

Supplementary Table 3. The baseline characteristics of the patients from the derivation and validation cohorts (LSM cohort)

Characteristic	Derivation cohort	Validation cohort	P-value
Total	2,141	2,141	
Age (years)	55.6±12.2	55.7±12.3	0.746
Male sex	1,212 (56.6)	1,155 (53.9)	0.080
HBV infection	699 (32.6)	676 (31.6)	0.452
HCV infection	65 (3.0)	66 (3.1)	0.929
NAFLD	794 (37.1)	787 (36.8)	0.825
Type 2 diabetes mellitus	491 (22.9)	503 (23.5)	0.664
Hypertension	1,164 (54.4)	1,126 (52.6)	0.244
Hypercholesterolemia	1,182 (55.2)	1,182 (55.2)	0.999
Body mass index (kg/m ²)	26 (23–29)	26 (23–28)	0.654
ALT (IU/L)	25 (18–39)	26 (18–39)	0.461
Albumin (g/L)	43.6±3.1	43.6±3.1	0.853
Total bilirubin (μmol/L)	10.6 (7.9–14.1)	10.4 (8.0–13.8)	0.281
ALP (IU/L)	67 (56–80)	67 (56–82)	0.362
AFP (μg/L)	2.8 (2.0–4.1)	2.7 (1.9–4.1)	0.472
WCC (×10 ⁹ /L)	6.5±1.9	6.7±2.0	0.036
Platelet (×10 ⁹ /L)	213 (173–253)	215 (177–257)	0.249
Prothrombin time (seconds)	10.7 (10.2–11.3)	10.7 (10.1–11.3)	0.235
INR	1.0 (0.9–1.0)	1.0 (0.9–1.0)	0.330
Triglycerides (mmol/L)	1.1 (0.8–1.7)	1.2 (0.8–1.7)	0.452
Cholesterol (mmol/L)	4.5 (3.9–5.2)	4.5 (3.8–5.2)	0.326
FBS (mmol/L)	6.0 (5.1–7.6)	6.0 (5.0–7.8)	0.801
Haemoglobin A1c (%)	6.7 (5.8–7.7)	6.7 (5.8–7.8)	0.920
Positive HBeAg*	112 (19.8)	101 (18.3)	0.535
HBV DNA* (log ₁₀ IU/mL)	4 (3–6)	4 (3–6)	0.111
Creatinine (μmol/L)	75 (62–89)	75 (62–88)	0.613
eGFR (mL/min/1.73 m ²)	92.7 (76.9–104.4)	92.6 (76.9–103.9)	0.911
Urea (mmol/L)	5.1 (4.2–6.2)	5.1 (4.3–6.3)	0.626
LSM (kPa)	5.9 (4.5–8.0)	5.9 (4.6–7.9)	0.711
CAP (dB/m)	262 (216–312)	262 (218–309)	0.816
Medication use			
Statins	907 (42.4)	900 (42.0)	0.829
Anti-platelet drugs	421 (19.7)	413 (19.3)	0.758
Antiviral treatment	334 (15.6)	291 (13.6)	0.063

Values are presented as mean±standard deviation, median (interquartile range), or number (%).

LSM, liver stiffness measurement; HBV, hepatitis B virus; HCV, hepatitis C virus; NAFLD, nonalcoholic fatty liver disease; ALT, alanine aminotransferase; ALP, alkaline phosphatase; AFP, alpha-fetoprotein; WCC, white cell count; INR, international normalized ratio; FBS, fasting blood sugar level; HBeAg, hepatitis B e antigen; eGFR, estimated glomerular filtration rate; CAP, controlled attenuation parameter.

*HBeAg and HBV DNA data are only shown among chronic hepatitis B patients. HCV RNA data are not reported as very few patients who had HCV RNA checked.